Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy

• Published in: JHEP reports Vol. 5; no. 5; p. 100713
• Main Authors: Weber, Nicholas D., Odriozola, Leticia, Ros-Gañán, Irene, García-Porrero, Guillermo, Salas, David, Argemi, Josepmaria, Combal, Jean-Philippe, Kishimoto, Takashi K., González-Aseguinolaza, Gloria
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2023; Elsevier
• Subjects: Child; Immunological tolerance; Liver cancer; Metabolic disorders; NAFLD; ALP; IHC; ABCB4; F; ALT; E-cadherin; M; CK19; Liver cancer; MDR2; ANOVA; γH2ax; qPCR; AAV8; MDR3; Child; CHOL; RT-qPCR; WT; NAbs; AST; Col1a1; BIL; KO; H&E; Timp1; HCC; p.i; PFIC3; Gapdh; Immunological tolerance; IV; rAAV; vg; PC; Lox; AAV; Metabolic disorders; BA
• ISSN: 2589-5559; 2589-5559
• DOI: 10.1016/j.jhepr.2023.100713

Gene therapy using recombinant adeno-associated virus (rAAV) vector carrying multidrug resistance protein 3 (MDR3) coding sequence (AAV8-MDR3) represents a potential curative treatment for progressive familial intrahepatic cholestasis type 3 (PFIC3), which presents in early childhood. However, patients with the severest form of PFIC3 should receive treatment early after detection to prevent irreversible hepatic fibrosis leading ultimately to liver transplantation or death. This represents a challenge for rAAV-based gene therapy because therapeutic efficacy is expected to wane as rAAV genomes are lost owing to hepatocyte division, and the formation of AAV-specific neutralising antibodies precludes re-administration. Here, we tested a strategy of vector re-administration in infant PFIC3 mice with careful evaluation of its oncogenicity – a particular concern surrounding rAAV treatment. AAV8-MDR3 was re-administered to infant Abcb4-/- mice 2 weeks after a first dose co-administered with tolerogenic nanoparticles carrying rapamycin (ImmTOR) given at 2 weeks of age. Eight months later, long-term therapeutic efficacy and safety were assessed with special attention paid to the potential oncogenicity of rAAV treatment. Co-administration with ImmTOR mitigated the formation of rAAV-specific neutralising antibodies and enabled an efficacious second administration of AAV8-MDR3, resulting in stable correction of the disease phenotype, including a restoration of bile phospholipid content and healthy liver function, as well as the prevention of liver fibrosis, hepatosplenomegaly, and gallstones. Furthermore, efficacious repeat rAAV administration prevented the appearance of liver malignancies in an animal model highly prone to developing hepatocellular carcinoma. These outcomes provide strong evidence for rAAV redosing through co-administration with ImmTOR, as it resulted in a long-term therapeutic effect in a paediatric liver metabolic disorder, including the prevention of oncogenesis. Redosing of gene therapy for inborn hepatobiliary disorders may be essential as effect wanes during hepatocyte division and renewal, particularly in paediatric patients, but the approach may carry long-term risks of liver cancer. Viral vectors carrying a therapeutic gene exerted a durable cure of progressive familial intrahepatic cholestasis type 3 in infant mice and reduced the risk of liver cancer only following a second administration. [Display omitted] •Gene therapy redosing may be necessary to maintain efficacy in paediatric patients with inborn hepatobiliary disorders.•Co-administration with tolerogenic nanoparticles carrying rapamycin enabled an efficacious second administration of AAV.•Only following a second AAV dose after treatment with AAV plus ImmTOR did infant PFIC3 mice exhibit a therapeutic effect.•Repeat administration also prevented the appearance of liver malignancies in mice prone to hepatocellular carcinoma.